The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Regulation of the p53 Tumor Suppressor Protein
Open accessAbstract
c-Jun N-terminal kinase Mutations in the p53 tumor suppressor gene occur in about 50% of all human tumors, making it the most frequent target for genetic alterations in cancer (for recent reviews on p53 see Refs. 1Hansen R. Oren M. Curr. Opin. Genet. Dev. 1997; 7: 46-51Crossref PubMed Scopus (206) Google Scholar, 2Levine A.J. Cell. 1997; 88: 323-331Abstract Full Text Full Text PDF PubMed Scopus (6697) Google Scholar, 3Agarwal M.L. Taylor W.R. Chernov M.V. Chernova O.B. Stark G.R. J. Biol. Chem. 1998; 273: 1-4Abstract Full Text Full Text PDF PubMed Scopus (646) Google Scholar, 4Almog N. Rotter V. Biochim. Biophys. Acta. 1998; 1378: R43-R54PubMed Google Scholar, 5Prives C. Hall P.A. J. Pathol. 1999; 187: 112-126Crossref PubMed Scopus (1225) Google Scholar). Such mutations probably facilitate carcinogenesis primarily through abrogating the tumor suppressor activities of the wild type p53 protein, although at least some forms of tumor-associated mutant p53 proteins may also contribute overt oncogenic activities (gain of function). Excessive wild type p53 activity gives rise to a variety of cellular outcomes, most notably cell cycle arrest and apoptosis. These cellular effects of wild type p53 can reduce cancer incidence through elimination of cancer-prone cells from the replicative pool. However, such effects might become very undesirable if occurring in a normal, unperturbed cell. p53 activity must therefore be kept under tight control, being unleashed only when a cell accumulates lesions that may otherwise drive it into a cancerous state. The signals and mechanisms that regulate p53 activity, maintaining it at low levels under normal conditions and turning it on in cancer-prone cells, are the subject of this review.p53-activating SignalsUnder normal conditions, p53 is most probably latent. Consequently, it does not interfere with cell cycle progression and cell survival. Moreover, p53 knock-out mice appear in most cases to undergo proper development and maturation (6Donehower L.A. Harvey M. Slagle B.L. Mcarthur M.J. Montgomery C.A. Butel J.S. Bradley A. Nature. 1992; 356: 215-221Crossref PubMed Scopus (4009) Google Scholar), suggesting that p53 is not essential for the normal performance of cells within the body. However, a variety of conditions can lead to rapid induction of p53 activity (Fig. 1). The common denominator of these conditions is that they represent various types of stress, which are likely to favor the emergence of cancer-bound cells. Such conditions include direct DNA damage (7Kastan M.B. Onyekwere O. Sidransky D. Vogelstein B. Craig R.W. Cancer Res. 1991; 51: 6304-6311PubMed Google Scholar, 8Maltzman W. Czyzyk L. Cell. Biol. PubMed Scopus Google Scholar, A. PubMed Scopus Google damage to in the proper and of the cellular genetic the C.A. C.A. PubMed Scopus Google L.A. A. Dev. PubMed Scopus Google Scholar), C. A.J. Nature. PubMed Scopus Google Scholar), A. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar), and to A. PubMed Scopus Google Scholar). of is a the rapid induction of p53 activity in to damage to that cells such damage are p53 may also to DNA M.L. A.J. Google Scholar, R. D. Rotter V. 1999; PubMed Scopus Google Scholar). The of p53 in maintaining it the of the Nature. 1992; PubMed Scopus Google Scholar). p53 activity is a variety of oncogenic and D. PubMed Scopus Google Scholar, M. D. Cell. 1997; 88: Full Text Full Text PDF PubMed Scopus Google Scholar, M. Dev. 7: PubMed Scopus Google Scholar, A. A. M. J. B. Oren M. J. 1999; PubMed Scopus Google Scholar), a direct oncogenic and the tumor suppressor of p53 of p53 induction of the p53 through alterations in the p53 in the of of the p53 gene a if in such Consequently, the of the p53 gene very recent not that the of is it that p53 levels rise A.J. Nature. PubMed Scopus Google Scholar). rise may be of the of for in the p53 D. Oren M. M. J. Google to the of the p53 gene to the and to be D. B. J. Rotter V. Google Scholar). The induction of and may at However, it does DNA and are at of DNA damage and rise to cancer-prone cells. of p53 levels under such conditions the cells in a of is DNA damage stress, p53 and does not interfere with normal cellular However, if conditions that for a p53 the of levels of p53 that such a be rapid and of p53 of cells to signals can lead within a to a in p53 some this can be of the p53 probably of a through the of this J. PubMed Scopus Google Scholar). also that p53 can p53 through to J. C. W. J. PubMed Scopus Google Scholar, C.A. Cell. Biol. 1997; PubMed Scopus Google Scholar). it is that the of p53 in to through is the in the of p53 is a very protein, turning with a a A. M. C.A. Oren M. Cell. Biol. PubMed Scopus Google Scholar). to DNA damage and types of stress, p53 is (7Kastan M.B. Onyekwere O. Sidransky D. Vogelstein B. Craig R.W. Cancer Res. 1991; 51: 6304-6311PubMed Google Scholar, 8Maltzman W. Czyzyk L. Cell. Biol. PubMed Scopus Google Scholar). rapid in p53 a for is in cells with is mos
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Self-citationRegulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J. (1996) · Nature · doi:10.1038/379088a0 · Cited by 2,300
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100
Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
Honda, R., Tanaka, H., & Yasuda, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01480-4 · Cited by 1,951
Research works printed but not linked: 68
- Hansen, 1997, Curr. Opin. Genet. Dev., 7, 46, 10.1016/S0959-437X(97)80108-6 · DOI · Paper page
- Levine, 1997, Cell, 88, 323, 10.1016/S0092-8674(00)81871-1 · DOI · Paper page
- Agarwal, 1998, J. Biol. Chem., 273, 1, 10.1074/jbc.273.1.1 · DOI · Paper page
- Almog, 1998, Biochim. Biophys. Acta, 1378, R43
- Prives, 1999, J. Pathol., 187, 112, 10.1002/(SICI)1096-9896(199901)187:1<112::AID-PATH250>3.0.CO;2-3 · doi:10.1002/(sici)1096-9896(199901)187:1<112::aid-path250>3.0.co;2-3
- Kastan, 1991, Cancer Res., 51, 6304
- Maltzman, 1984, Mol. Cell. Biol., 4, 1689
- Huang, 1996, Proc. Natl. Acad. Sci. U. S. A., 93, 4827, 10.1073/pnas.93.10.4827 · DOI · Paper page
- Cross, 1995, Science, 267, 1353, 10.1126/science.7871434 · DOI · Paper page
- Linke, 1996, Genes Dev., 10, 934, 10.1101/gad.10.8.934 · DOI · Paper page
- Ohnishi, 1996, J. Biol. Chem., 271, 14510, 10.1074/jbc.271.24.14510 · DOI
- Forrester, 1996, Proc. Natl. Acad. Sci. U. S. A., 93, 2442, 10.1073/pnas.93.6.2442 · DOI · Paper page
- Smith, 1995, Oncogene, 10, 1053
- Offer, 1999, FEBS Lett., 450, 197, 10.1016/S0014-5793(99)00505-0 · DOI
- Hermeking, 1994, Science, 265, 2091, 10.1126/science.8091232 · DOI · Paper page
- Debbas, 1993, Gene Dev., 7, 546, 10.1101/gad.7.4.546 · DOI · Paper page
- Damalas, 1999, EMBO J., 18, 3054, 10.1093/emboj/18.11.3054 · DOI · Paper page
- Reich, 1984, Nature, 308, 199, 10.1038/308199a0 · DOI · Paper page
- Ginsberg, 1990, Oncogene, 5, 1285
- Reisman, 1993, Cell Growth Differ., 4, 57
- Fu, 1996, EMBO J., 15, 4392, 10.1002/j.1460-2075.1996.tb00812.x · DOI
- Mosner, 1995, EMBO J., 14, 4442, 10.1002/j.1460-2075.1995.tb00123.x · DOI · Paper page
- Fontoura, 1997, Mol. Cell. Biol., 17, 3146, 10.1128/MCB.17.6.3146 · DOI
- Rogel, 1985, Mol. Cell. Biol., 5, 2851
- Hupp, 1992, Cell, 71, 875, 10.1016/0092-8674(92)90562-Q · DOI · Paper page
- Bayle, 1995, Proc. Natl. Acad. Sci. U. S. A., 92, 5729, 10.1073/pnas.92.12.5729 · DOI
- Wolkowicz, 1995, Proc. Natl. Acad. Sci. U. S. A., 92, 6842, 10.1073/pnas.92.15.6842 · DOI
- Hupp, 1995, J. Biol. Chem., 270, 18165, 10.1074/jbc.270.30.18165 · DOI
- Gu, 1997, Cell, 90, 595, 10.1016/S0092-8674(00)80521-8 · DOI · Paper page
- Waterman, 1998, Nat. Genet., 19, 175, 10.1038/542 · DOI · Paper page
- Lambert, 1998, J. Biol. Chem., 273, 33048, 10.1074/jbc.273.49.33048 · DOI · Paper page
- Shaulsky, 1990, Oncogene, 5, 1707
- Lozano, 1998, Biochim. Biophys. Acta, 1377, M55
- Freedman, 1999, Cell. Mol. Life Sci., 55, 96, 10.1007/s000180050273 · DOI · Paper page
- Juven-Gershon, 1999, Mol. Med., 5, 71, 10.1007/BF03402141 · DOI
- Chen, 1996, Mol. Cell. Biol., 16, 2445, 10.1128/MCB.16.5.2445 · DOI · Paper page
- Haupt, 1996, EMBO J., 15, 1596, 10.1002/j.1460-2075.1996.tb00504.x · DOI · Paper page
- Thut, 1995, Science, 267, 100, 10.1126/science.7809597 · DOI · Paper page
- Lu, 1995, Proc. Natl. Acad. Sci. U. S. A., 92, 5154, 10.1073/pnas.92.11.5154 · DOI · Paper page
- Thut, 1997, Gene Dev., 11, 1974, 10.1101/gad.11.15.1974 · DOI · Paper page
- Barak, 1993, EMBO J., 12, 461, 10.1002/j.1460-2075.1993.tb05678.x · DOI · Paper page
- Wu, 1993, Genes Dev., 7, 1126, 10.1101/gad.7.7a.1126 · DOI · Paper page
- Perry, 1993, Proc. Natl. Acad. Sci. U. S. A., 90, 11623, 10.1073/pnas.90.24.11623 · DOI
- Wu, 1997, Mol. Med., 3, 441, 10.1007/BF03401691 · DOI · Paper page
- Landers, 1994, Oncogene, 9, 2745
- Sun, 1998, Science, 282, 2270, 10.1126/science.282.5397.2270 · DOI · Paper page
- Maki, 1996, Cancer Res., 56, 2649
- Kubbutat, 1997, Mol. Cell. Biol., 17, 460, 10.1128/MCB.17.1.460 · DOI · Paper page
- Fuchs, 1998, Genes Dev., 12, 2658, 10.1101/gad.12.17.2658 · DOI · Paper page
- Fuchs, 1998, Oncogene, 17, 1483, 10.1038/sj.onc.1202184 · DOI
- Meek, 1998, Cell. Signal., 10, 159, 10.1016/S0898-6568(97)00119-8 · DOI
- Giaccia, 1998, Genes Dev., 12, 2973, 10.1101/gad.12.19.2973 · DOI · Paper page
- Jayaraman, 1999, Cell. Mol. Life Sci., 55, 76, 10.1007/s000180050271 · DOI
- Shieh, 1999, EMBO J., 18, 1815, 10.1093/emboj/18.7.1815 · DOI · Paper page
- Unger, 1999, EMBO J., 18, 1805, 10.1093/emboj/18.7.1805 · DOI · Paper page
- Banin, 1998, Science, 281, 1674, 10.1126/science.281.5383.1674 · DOI · Paper page
- Canman, 1998, Science, 281, 1677, 10.1126/science.281.5383.1677 · DOI · Paper page
- Khanna, 1995, Oncogene, 11, 609
- Blattner, 1999, Oncogene, 18, 1723, 10.1038/sj.onc.1202480 · DOI · Paper page
- Mayo, 1997, Cancer Res., 57, 5013
- Kubbutat, 1999, Cell Growth Differ., 10, 87
- Shaw, 1996, Oncogene, 12, 921
- Hupp, 1999, Cell Mol. Life Sci., 55, 88, 10.1007/s000180050272 · DOI
- de Stanchina, 1998, Genes Dev., 12, 2434, 10.1101/gad.12.15.2434 · DOI · Paper page
- Palmero, 1998, Nature, 395, 125, 10.1038/25870 · DOI · Paper page
- Bates, 1998, Nature, 395, 124, 10.1038/25867 · DOI · Paper page
- Shaulian, 1997, Oncogene, 15, 2717, 10.1038/sj.onc.1201453 · DOI
- Leri, 1999, Am. J. Pathol., 154, 567, 10.1016/S0002-9440(10)65302-3 · DOI
Cited by
How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression
Aubrey, B. J., Kelly, G. L., Janic, A., Herold, M. J., & Strasser, A. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.169 · Cited by 1,395
Inhibiting the p53–MDM2 interaction: an important target for cancer therapy
Chène, P. (2003) · Nature Reviews Cancer · doi:10.1038/nrc991 · Cited by 765
ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage
Maya, R., Balass, M., Kim, S.-T., Shkedy, D., Leal, J.-F. M., Shifman, O., Moas, M., Buschmann, T., Ronai, Z., Shiloh, Y., et al. (2001) · Genes & Development · doi:10.1101/gad.886901 · Cited by 731
“This negative auto-regulatory feedback loop enables the tight regulation of p53 activity and stability (Freedman and Levine 1999; Juven-Gershon and Oren 1999; Momand et al. 2000).”
BackgroundInfluentialSelf-citationOscillatory Expression of Hes1, p53, and NF-κB Driven by Transcriptional Time Delays
Monk, N. A. M. (2003) · Current Biology · doi:10.1016/s0960-9822(03)00494-9 · Cited by 708
A p53 Amino-Terminal Nuclear Export Signal Inhibited by DNA Damage-Induced Phosphorylation
Zhang, Y., & Xiong, Y. (2001) · Science · doi:10.1126/science.1058637 · Cited by 378
Metadata
- Authors
- Oren, M.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1999-12
- Volume
- 274
- Issue
- 51
- Pages
- 36031-36034
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2148958834
- Cited by
- 564
- References
- 23
- FWCI
- 21.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 7617 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Regulation of the p53 Tumor Suppressor Protein. https://app.cochat.ai/papers/10.1074/jbc.274.51.36031
- The paper
- Oren, M. (1999). Regulation of the p53 Tumor Suppressor Protein. Journal of Biological Chemistry. https://doi.org/10.1074/jbc.274.51.36031
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.